TScan Therapeutics (TCRX) Balance Sheet: Assets & Liabilities

TScan Therapeutics (TCRX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), TScan Therapeutics reported total assets of $228.79M and total liabilities of $105.67M. Shareholders' equity was $123.12M, down 48.9% from $240.97M a year earlier. Total debt stood at $39.70M against $152.41M in cash and short-term investments, a net cash position of $112.70M. That puts debt-to-equity at 0.32, compared with 0.15 a year earlier.

TScan Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for TScan Therapeutics, Inc. (TCRX) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Current Assets
Cash and Cash Equivalents	152.41	178.69	133.36	120.03	161.41	34.79	41.76
Short-Term Investments	0.00	111.42	58.69	0.00	0.00	0.00	0.00
Cash & Short-Term Investments	152.41	290.11	192.04	120.03	161.41	34.79	41.76
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	4.80	2.61	2.19	4.10	4.25	1.65	0.62
Total Current Assets	157.21	292.72	194.24	124.13	165.65	36.45	42.38
Non-Current Assets
Property, Plant & Equipment (Net)	66.45	71.60	71.23	69.20	17.26	12.53	6.41
Long-Term Investments	5.03	0.00	0.00	5.04	5.20	0.00	0.00
Other Non-Current Assets	5.13	6.80	6.68	5.76	0.00	0.76	0.60
Total Non-Current Assets	71.58	78.40	77.91	74.96	22.45	13.29	7.00
Total Assets	228.79	371.12	272.15	199.09	188.11	49.74	49.38
Current Liabilities
Accounts Payable	1.24	4.28	2.37	2.91	1.77	2.91	1.01
Short-Term Debt	7.17	4.57	6.59	3.68	1.65	1.42	0.44
Current Portion of Long-Term Debt	-	-	3.35	-	-	-	-
Accrued Liabilities	3.33	8.49	4.81	2.05	2.91	2.36	-
Deferred Revenue	2.62	11.70	10.14	3.87	11.41	10.63	0.00
Other Current Liabilities	0.20	0.08	10.72	0.43	6.52	0.13	0.94
Total Current Liabilities	18.70	35.96	29.82	17.31	21.34	17.45	2.40
Non-Current Liabilities
Long-Term Debt	32.53	32.07	85.84	29.29	4.39	6.02	4.44
Other Non-Current Liabilities	0.00	0.14	0.00	0.05	0.10	0.24	0.00
Total Non-Current Liabilities	86.97	94.19	91.46	82.35	5.99	74.75	4.44
Total Liabilities	105.67	130.15	121.28	99.66	27.33	32.52	6.84
Stockholders' Equity
Common Stock	0.01	0.01	0.01	0.00	0.00	0.00	0.00
Retained Earnings	-504.86	-375.10	-247.60	-158.38	-92.16	-43.53	-17.41
Accumulated Other Comprehensive Income	0.00	0.05	0.00	0.00	0.00	0.00	0.00
Additional Paid-in Capital	627.98	616.01	398.46	257.81	252.93	1.07	0.27
Shares Outstanding	56.90	56.59	47.83	24.23	23.91	-	-
Total Stockholders' Equity	123.12	240.97	150.87	99.43	160.78	17.22	42.54
Total Liabilities & Equity	228.79	371.12	272.15	199.09	188.11	49.74	49.38

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About TScan Therapeutics Balance Sheet

How much debt does TScan Therapeutics have?

TScan Therapeutics had total debt of $39.70M as of Dec 31, 2025, against $152.41M in cash and short-term investments. Its debt-to-equity ratio was 0.32. Total debt was $36.64M a year earlier.

What are TScan Therapeutics's total assets?

TScan Therapeutics reported total assets of $228.79M as of Dec 31, 2025, down 38.4% from $371.12M a year earlier. Total liabilities were $105.67M.

What is TScan Therapeutics's shareholders' equity?

TScan Therapeutics's shareholders' equity was $123.12M as of Dec 31, 2025, or about $2.16 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition